Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 460,697
  • Shares Outstanding, K 224,730
  • Annual Sales, $ 20 K
  • Annual Income, $ -257,590 K
  • EBIT $ -227 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.50

Options Overview Details

View History
  • Implied Volatility 307.51% (+120.23%)
  • Historical Volatility 111.67%
  • IV Percentile 75%
  • IV Rank 35.55%
  • IV High 700.73% on 11/17/25
  • IV Low 90.58% on 03/27/25
  • Expected Move (DTE 27) 0.31 (15.34%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 779
  • Volume Avg (30-Day) 595
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 11,869
  • Open Int (30-Day) 8,955
  • Expected Range 1.74 to 2.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 8
  • High Estimate -0.18
  • Low Estimate -0.42
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 +41.38%
on 01/29/26
2.30 -10.87%
on 02/19/26
+0.48 (+30.57%)
since 01/20/26
3-Month
1.20 +70.83%
on 11/21/25
2.30 -10.87%
on 02/19/26
+0.81 (+65.32%)
since 11/20/25
52-Week
0.86 +137.79%
on 05/14/25
2.39 -14.23%
on 02/21/25
-0.21 (-9.09%)
since 02/20/25

Most Recent Stories

More News
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

ALLO : 2.05 (-3.76%)
Record $2.5B Sector Start Spotlights Clinical Oncology Plays

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is surging toward $668.26 billion by 2034 with an 11.50% CAGR as innovative...

ALLO : 2.05 (-3.76%)
ONCY : 0.9640 (-3.60%)
IMNM : 21.50 (-2.89%)
LLY : 1,009.52 (-1.34%)
KURA : 8.46 (-1.40%)
AMGN : 374.75 (-0.20%)
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with...

ALLO : 2.05 (-3.76%)
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan...

ALLO : 2.05 (-3.76%)
CLLS : 3.90 (-2.26%)
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

ALLO : 2.05 (-3.76%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 2.05 (-3.76%)
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

ALLO : 2.05 (-3.76%)
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...

ALLO : 2.05 (-3.76%)
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan

Allogene Therapeutics received a Sell rating and price target from J.P. Morgan analyst Brian Cheng today. The company’s shares closed yesterday at $1.27.Elevate Your Investing Strategy: Take advantage...

ALLO : 2.05 (-3.76%)
J.P. Morgan Sticks to Its Sell Rating for Allogene Therapeutics (ALLO)

In a report released today, Brian Cheng from J.P. Morgan maintained a Sell rating on Allogene Therapeutics. The company’s shares closed yesterday at $1.51.Elevate Your Investing Strategy: Take advantage...

ALLO : 2.05 (-3.76%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 2.21
2nd Resistance Point 2.17
1st Resistance Point 2.11
Last Price 2.05
1st Support Level 2.01
2nd Support Level 1.97
3rd Support Level 1.91

See More

52-Week High 2.39
Last Price 2.05
Fibonacci 61.8% 1.81
Fibonacci 50% 1.63
Fibonacci 38.2% 1.45
52-Week Low 0.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar